Stockreport

Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab [Yahoo! Finance]

Tiziana Life Sciences Ltd - Common Shares  (TLSA) 
PDF FDA Allowance for an additional 20 Patients to be enrolled in the intranasal foralumab Multiple Sclerosis Expanded Access Program will allow further data collection and [Read more]